CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 150 enrolled
Drug / intervention
intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution +1 moreother
Likely dose
intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solutionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02629835
NCT02629835Phase 3Completed

A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks

Montreal General Hospital·interventional·Posted Dec 14, 2015·Updated Mar 22, 2017

In Brief

A Phase 3 clinical trial evaluating intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution and intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone for Brachial Plexus Block Duration. Completed, enrolled 150 participants across 3 sites in 2 countries.

Detailed Summary

Dexamethasone prolong the duration of brachial plexus blocks, but the optimal route, intravenous (IV) or perineural (PN), remains controversial. This Multi-centric trial compare IV and PN dexamethasone for ultrasound-guided axillary brachial plexus blocks (AXBs). Research hypothesis is that PN modality will outlast its IV counterpart. Since analgesic duration and sensory duration can be influenced by intake of pain medications and surgical trauma to small cutaneous nerves, the investigators will select motor block duration as the main outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Thailand
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 14, 2015
Enrollment StartJan 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.5 years ago

Interventions

intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solutionother

intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasoneother